Issue Information
20 June 2019
Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C
Kathleen B. Schwarz, Philip Rosenthal, Karen F. Murray, Jonathan R. Honegger, Winita Hardikar, Rosie Hague, Naveen Mittal, Benedetta Massetto, Diana M. Brainard, Chia‐Hsiang Hsueh, Jiang Shao, Bandita Parhy, Michael R. Narkewicz, Girish S. Rao, Suzanne Whitworth, Sanjay Bansal, William F. Balistreri – 20 June 2019 – For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents.
Considering the Links Between Nonalcoholic Fatty Liver Disease and Insulin Resistance: Revisiting the Role of Protein Kinase C ε
Varman T. Samuel, Max C. Petersen, Brandon M. Gassaway, Daniel F. Vatner, Jesse Rinehart, Gerald I. Shulman – 20 June 2019
Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant
Runping Liu, Jason D. Kang, R. Balfour Sartor, Masoumeh Sikaroodi, Andrew Fagan, Edith A. Gavis, Huiping Zhou, Phillip B. Hylemon, Jeremy W. Herzog, Xiaojiaoyang Li, Robert H. Lippman, Javier Gonzalez‐Maeso, James B. Wade, Siddhartha Ghosh, Emily Gurley, Patrick M. Gillevet, Jasmohan S. Bajaj – 20 June 2019 – Cirrhosis and hepatic encephalopathy (HE) is associated with an altered gut–liver–brain axis. Fecal microbial transplant (FMT) after antibiotics improves outcomes in HE, but the impact on brain function is unclear.
Issue Information ‐ Meeting Notices
20 June 2019
Exome Sequencing in Clinical Hepatology
Sílvia Vilarinho, Pramod K. Mistry – 20 June 2019 – The clinical relevance of the Human Genome Project and next‐generation sequencing technology was demonstrated for the first time in 2009, when whole‐exome sequencing (WES) provided the definitive diagnosis of congenital chloride diarrhea in an infant with presumed renal salt‐wasting disease. Over the past decade, numerous studies have shown the utility of WES for clinical diagnosis as well as for discovery of novel genetic disorders through analysis of a single or a handful of informative pedigrees.
Letter to the Editor: Hepatocellular Carcinoma Surveillance in High‐Risk Patients With Cirrhosis: Contrast‐Enhanced Ultrasound May Be a Choice
Jiangfa Li, Jiming Wang, Shuiping Yu, Guandou Yuan, Songqing He – 20 June 2019
Issue Information ‐ Author Checklist
20 June 2019
A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation
Elizabeth J. Carey, Jennifer C. Lai, Christopher Sonnenday, Elliot B. Tapper, Puneeta Tandon, Andres Duarte‐Rojo, Michael A. Dunn, Cynthia Tsien, Eric R. Kallwitz, Vicky Ng, Srinivasan Dasarathy, Matthew Kappus, Mustafa R. Bashir, Aldo J. Montano‐Loza – 20 June 2019 – Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population.
Long‐Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents
Fasiha Kanwal, Jennifer R. Kramer, Steven M. Asch, Yumei Cao, Liang Li, Hashem B. El‐Serag – 20 June 2019 – Sustained virologic response (SVR) after direct acting antiviral agents (DAAs) holds promise for reducing hepatocellular cancer (HCC). DAAs have recently been available long enough to estimate the long‐term risk. We conducted a retrospective cohort study of hepatitis C virus (HCV) patients who achieved SVR with DAAs from 129 Veterans Health Administration hospitals between January 1, 2015, and December 31, 2015, with follow‐up through September 30, 2018.